These 5 cases illustrate that initiation of exon skipping therapies before age 3 is feasible and provide further evidence of safety. Based upon extrapolation from other studies, treatment in this age group is likely to provide long-term benefits.
2024 / Therapies, Duchenne, Exon skipping, Mutation-specific therapy, Treatment access

These 5 cases illustrate that initiation of exon skipping therapies before age 3 is feasible and provide further evidence of safety. Based upon extrapolation from other studies, treatment in this age group is likely to provide long-term benefits.